je.st

Home › biopharmaceutical

Tag: biopharmaceutical

Bucks County biopharmaceutical firm cutting its work force in half

2015-04-17 12:30:13| Biotech - Topix.net

Discovery Laboratories is cutting its workforce in half and voluntarily ceasing the commercialization of what had been its lead product as part of a restructuring plan announced late Thursday afternoon. The move will result in the elimination of about 50 jobs at the Warrington, Pa., biopharmaceutical company.

Tags: work half county force

The top biopharmaceutical deals of 2014

2014-12-15 16:30:41| Biotech - Topix.net

In January, Teva made an unsolicited offer to buy NuPathe Inc. of Malvern, Pa., for $114 million - topping a $105 million offer Endo International put in play at the end of 2013. Teva ultimately bought NuPathe, the developer of the migraine headache treatment Zecuity, for $144 billion in February.

Tags: top deals deals top biopharmaceutical

UNIGEN, Japan: MES for Complex Biopharmaceutical Production Implemented in Only Four Months ...

2014-08-13 06:00:00| Industrial Newsroom - All News for Today

World's largest biotech plant for contract manufacturing of recombinant influenza vaccines set up / PAS-X standard software product, fast-track implementation and MBR modeling accelerate MES deployment<br /> <br /> Lüneburg, Germany – The Japanese biotech company UNIGEN Inc. has taken Werum's PAS-X Manufacturing Execution System (MES) into operation within a record time of only four months. The short implementation time was possible because the company relied on a standard ...This story is related to the following:Manufacturing Software |

Tags: only months japan production

How To Prepare A Facility For The Biopharmaceutical Revolution

2014-07-08 15:47:46| drugdiscoveryonline Home Page

Drug discovery is an inherently inefficient process. It takes thousands of failed compounds before one can get approved as safe and efficacious, and this effort does not come at a low cost. Because of this, the industry is constantly looking for ways to bring safe, compliant, and profitable drugs to market faster and cheaper. One avenue to achieve this that is growing in popularity is flexible factories and the utilization of single-use technology, both enabling low-cost biomanufacturing without sacrificing quality. In a recent article on Pharmaceutical Online, Merck’s Jeff Johnson stated if a company could achieve titers above 10 grams per liter in a single-use facility, there would no longer be a need to build stainless steel bioreactor facilities. This change is one he believes would alter the future of the pharmaceutical manufacturing industry. At Patheon’s mammalian cGMP production in Brisbane, Australia, single-use technology, in combination with internal patented technology, is being used to clarify cell densities at 200 million cells per milliliter and produce titers up to 20 grams per liter. With titers this high, the future Johnson suggested is becoming more possible and the Patheon facility exemplifies the facility needed to survive the future of pharma. But how did they do it?

Tags: the facility prepare revolution